Aspirin ad infinitum? Safety and efficacy of daily long-term antiplatelets
June 18, 2010
Recorded March 15, 2010

Is there evidence to support the long-term use of aspirin and other antiplatelet agents for patients with cardiovascular disease? In this animated exchange, Drs Eric Topol, John Cleland, and Bob Harrington ponder their safety and efficacy, question evidence and dogma, and review the data on aspirin for primary and secondary prevention, while addressing issues such as interpretation of meta-analyses, potential publication bias, and prevention of in-stent thrombosis.
Chair

Eric Topol MD
Director, Scripps Translational Science Institute
The Gary and Mary West Chair of Innovative Medicine
Chief Academic Officer, Scripps Health
La Jolla, CA

Dr Topol has no relevant financial relationships to declare.
Discussants

Bob Harrington MD
Professor of Medicine, Division of Cardiology
Director, Duke Clinical Research Institute
Durham, NC

To view Dr Harrington's disclosure statement, click here.


John Cleland MD
Professor of Cardiology
University of Hull
Head of Department, Cardiology
Castle Hill Hospital
Kingston-upon-Hull, UK

Dr Cleland has served as an advisor or consultant for Medtronic, Biotronik, and Merck Sharp & Dohme. He has served as a speaker or a member of a speaker's bureau for Merck Sharp & Dohme and Otsuka. Dr Cleland has received grants for clinical research from Amgen and Servier.




Related links: